Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

被引：0
|
作者：
Waldron, Christina [1 ]
Ito, Satoko [2 ]
Wang, Daniel [1 ]
Allen, Cecily [3 ]
Viswanathan, Giri [4 ]
Bona, Robert D. [5 ]
Cuker, Adam [6 ,7 ]
Goshua, George [2 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA
[3] Johns Hopkins Univ Hosp, Div Hematol, Dept Med, Baltimore, MD USA
[4] Yale Coll, New Haven, CT USA
[5] Yale Univ, Sect Hematol, Dept Internal Med, New Haven, CT USA
[6] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA USA
[7] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-188018
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States
    Waldron, Christina
    Ito, Satoko
    Wang, Daniel
    Allen, Cecily
    Viswanathan, Giri
    Cuker, Adam
    Goshua, George
    [J]. BLOOD, 2024, 143 (22) : 2332 - 2335
  • [2] Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease
    Machin, Nicoletta
    Ragni, Margaret V.
    [J]. BLOOD ADVANCES, 2020, 4 (14) : 3234 - 3238
  • [3] Cost-Effectiveness of Long-Term Prophylaxis Versus on-Demand Treatment with Von Willebrand Factor Concentrate in Severe Inherited Von Willebrand Disease
    Bhaskar, Anushka
    Connell, Nathan T.
    [J]. BLOOD, 2020, 136
  • [4] Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease
    Roussi, J
    Turecek, PL
    André, P
    Bonneau, M
    Pignaud, G
    Sollier, CBD
    Schlokat, U
    Dorner, F
    Schwarz, HP
    Drouet, L
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 (04) : 361 - 372
  • [5] Recombinant Von Willebrand factor concentrate in 2A Von Willebrand disease: comparison to plasma-derived Von Willebrand factor concentrate therapy
    Rajpurkar, Madhvi
    Frey, Mary Jane
    Sabo, Cynthia
    Hollon, Wendy
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2019, 30 (04) : 168 - 170
  • [6] Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
    Gritsch, Herbert
    Schrenk, Gerald
    Weinhappl, Nina
    Mellgard, Bjorn
    Ewenstein, Bruce
    Turecek, Peter L.
    [J]. JOURNAL OF BLOOD MEDICINE, 2022, 13 : 649 - 662
  • [7] Long-term prophylaxis in von Willebrand disease
    Berntorp, E
    Petrini, P
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2005, 16 : S23 - S26
  • [8] Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease
    Sidonio, Robert F., Jr.
    Boban, Ana
    Dubey, Leonid
    Inati, Adlette
    Kiss, Csongor
    Lissitchkov, Toshko
    Novik, Dzmitry
    Peteva, Elina
    Taher, Ali T.
    Timofeeva, Margarita Arkadevna
    Vilchevska, Kateryna V.
    Vdovin, Vladimir
    Werner, Sylvia
    Knaub, Sigurd
    Khayat, Claudia
    [J]. BLOOD, 2022, 140 : 8438 - 8439
  • [9] Recombinant von Willebrand factor for perioperative bleeding management in pediatric patient with allergy to plasma-derived von Willebrand factor
    Tran, Thuy B.
    Arnall, Justin R.
    Kleiboer, Brendan
    Hinson, Ashley
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70 (02)
  • [10] Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3
    Bauer, Alexander
    Friberg-Hietala, Sofia
    Smania, Giovanni
    Wolfsegger, Martin
    [J]. JOURNAL OF BLOOD MEDICINE, 2023, 14 : 399 - 411
12345